Seattle Genetics continues to actively monitor the impact of the COVID-19 global pandemic on our business, and we will adjust our approach as necessary.

SUPPLY OF OUR MEDICINES
We are always working to ensure the stability of our supply chain. At this time, we have not experienced and do not anticipate disruptions to the supply of our medicines due to the COVID-19 pandemic, including our three marketed products, ADCETRIS® (brentuximab vedotin), PADCEV™ (enfortumab vedotin-ejfv) and TUKYSA™ (tucatinib).

COMMERCIAL
To support COVID-19 containment measures and comply with stay home orders, our field-based personnel paused in-person interactions in healthcare settings and have been using digital means of ensuring continued support for healthcare professionals and patients. On April 17, 2020, the FDA approved our third marketed product, TUKYSA, in combination with trastuzumab and capecitabine for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. We are working to support a strong launch of TUKYSA throughout the U.S. In addition, we continue to work closely with our partner, Astellas, to support a strong launch of PADCEV for bladder cancer, which was approved by the FDA last December. Recently, following the appropriate guidance from relevant authorities, we have begun to slowly reintroduce in-person interactions for our field-based personnel where (i) state and local laws and regulations allow, (ii) the institution or office is accepting in-person interactions, and (iii) our field-based personnel are comfortable engaging in-person with healthcare providers. We will continue to monitor COVID-19 safety measures to help ensure that we are complying with the most current relevant guidance, which may mean an increase or decrease in our in-person interactions for the near future.

EMPLOYEES
The health and safety of our workforce is of the utmost importance and we have implemented measures designed to protect the health and safety of our workforce. These measures include a mandatory work-from-home policy for employees who can perform their jobs offsite. We are continuing our essential research and laboratory activities, and we are taking a number of additional precautionary measures designed to protect employees on site.

REGULATORY
The FDA and other regulatory agencies continue to be actively engaged with us on a variety of matters in the US and in other regions, including in Europe.

CLINICAL TRIALS
We are focused on improving the lives of patients with cancer and many of our trials provide an option for patients with unmet medical needs. We are working diligently to advance our clinical trial activities, while also actively assessing and working to mitigate risks to our patients, partners, employees, and clinical trial site personnel. We expect that the impact of COVID-19 on health care institutions in regions with significant numbers of cases will affect clinical trials. We will continue to actively review new information about COVID-19 and work closely with investigators and sites to follow evolving regulatory guidance regarding clinical trials.

Forward Looking Statements
Certain statements made in this fact sheet are forward looking, such as those, among others, relating to the research, development and commercialization of our products and product candidates, our manufacturing and product supply, workforce, sales and sales efforts, clinical trial activities and the COVID-19 pandemic. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include risks and uncertainties regarding the global spread and impact of the COVID-19 pandemic and its potential impacts on our business. More information about the risks and uncertainties faced by Seattle Genetics is contained under the caption “Risk Factors” included in the company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 filed with the Securities and Exchange Commission as updated by our subsequent Quarterly Reports on Form 10-Q and our other filings with the Securities and Exchange Commission. Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.